DGX RSI

What is DGX?

Quest Diagnostics traces its roots back to 1967, starting as Metropolitan Pathology Laboratories before evolving into the industry giant we know today. After being spun off from Corning in 1996, it solidified its position as a leader in diagnostic information services. The core business model is straightforward but massive: they operate a network of laboratories that provide clinical testing to physicians, hospitals, and even directly to patients. From basic blood panels to complex genetic testing, they handle millions of samples annually, turning raw data into actionable medical insights.

The service lineup is extensive. They specialize in routine clinical testing, non-invasive prenatal screening, and high-complexity molecular diagnostics. Historically, Quest has grown through strategic acquisitions, notably the 1999 purchase of SmithKline Beecham Clinical Laboratories, which significantly expanded their reach. They have successfully navigated the shift toward value-based care by becoming an essential partner for health systems looking to outsource their lab operations.

Financially, Quest is a steady performer with a solid balance sheet. They generate significant free cash flow and maintain a reliable dividend policy, making them a staple for defensive healthcare portfolios. While the pandemic provided a temporary boost through COVID testing, the company has successfully pivoted back to its core offerings and high-growth areas like oncology and neurology.

Looking toward 2026, Quest's strategy revolves around automation and artificial intelligence. They are investing heavily in digital pathology to speed up turnaround times and improve diagnostic accuracy. By 2026, expect a larger focus on consumer-facing healthcare through their QuestDirect platform, allowing patients to order their own tests. Additionally, the company aims to capitalize on the aging population and the trend of hospital systems divesting their in-house labs. Their focus on high-margin advanced diagnostics and operational efficiency through AI-driven logistics positions them well to outperform as healthcare becomes increasingly data-dependent.

What is RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and magnitude of price changes. Developed by J. Welles Wilder, RSI ranges from 0 to 100 and helps traders identify overbought or oversold conditions in an asset.

For DGX, monitoring the RSI provides valuable insights into potential trend reversals and entry/exit points. When the RSI drops below 30, Quest Diagnostics Inc. is typically considered oversold, suggesting the asset may be undervalued. Conversely, an RSI above 70 indicates overbought conditions.

Understanding DGX RSI Signals

• Oversold (RSI below 30): When DGX RSI falls below 30, it suggests the asset may have been sold off excessively and could be due for a bounce. This is often viewed as a potential buying opportunity, though it's important to consider other factors and not rely solely on RSI.
• Overbought (RSI above 70): An RSI above 70 indicates DGX may be overbought, potentially signaling a pullback or consolidation phase. Traders often use this as a signal to take profits or wait for better entry points.
• Divergences: When DGX price makes new highs or lows but RSI doesn't confirm these moves, it can signal weakening momentum and a possible trend reversal.

Daily vs Weekly RSI for DGX

This page displays both daily and weekly RSI for DGX. The daily RSI responds quickly to short-term price movements, making it useful for day traders and swing traders. The weekly RSI provides a broader perspective on momentum trends, helping longer-term investors identify major oversold or overbought conditions.

By analyzing both timeframes together, you can better understand Quest Diagnostics Inc.'s momentum at multiple levels and make more informed trading decisions.

Historical RSI Oversold Analysis

Above, we track historical instances when DGX RSI dropped below 30 (oversold territory). Reviewing these past oversold levels helps identify patterns and understand how Quest Diagnostics Inc. has historically responded to oversold conditions. Many traders use these historical reference points to gauge potential support levels and timing for entry positions.